{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:54:43Z","timestamp":1788155683419,"version":"build-2803163510"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["MA 3313\/2-1"],"award-info":[{"award-number":["MA 3313\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["JA 1847\/2-1"],"award-info":[{"award-number":["JA 1847\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009397","name":"Faculty of Medicine, University of T\u00fcbingen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009397","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Institute of Pathology, University Hospital T\u00fcbingen"},{"name":"State of Baden-W\u00fcrttemberg within the Centers for Personalized Medicine Baden-W\u00fcrttemberg"},{"name":"Mach-Gaensslen-Stiftung Schweiz"},{"name":"Dres. Bayer-Foundation"},{"DOI":"10.13039\/501100013362","name":"Swiss Cancer Research","doi-asserted-by":"publisher","award":["08-2020"],"award-info":[{"award-number":["08-2020"]}],"id":[{"id":"10.13039\/501100013362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["101116768"],"award-info":[{"award-number":["101116768"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["EXC 2180-390900677"],"award-info":[{"award-number":["EXC 2180-390900677"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["INST 37\/1228-1 FUGG"],"award-info":[{"award-number":["INST 37\/1228-1 FUGG"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["INST 37\/1302-1 FUGG"],"award-info":[{"award-number":["INST 37\/1302-1 FUGG"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Brigitte and Dr. Konstanze Wegener-Stiftung"},{"name":"Werner Jackst\u00e4dt-Stiftung"},{"DOI":"10.13039\/501100008751","name":"Bundesinstitut f\u00fcr Risikobewertung","doi-asserted-by":"publisher","award":["Bf3R, 60-0102-01.P641-12572660"],"award-info":[{"award-number":["Bf3R, 60-0102-01.P641-12572660"]}],"id":[{"id":"10.13039\/501100008751","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005968","name":"Leukemia Research Foundation","doi-asserted-by":"publisher","award":["1077776"],"award-info":[{"award-number":["1077776"]}],"id":[{"id":"10.13039\/100005968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"Chinese Scholarship Council","doi-asserted-by":"crossref","award":["202108370099"],"award-info":[{"award-number":["202108370099"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006603","name":"BMBF","doi-asserted-by":"publisher","award":["01KT1907"],"award-info":[{"award-number":["01KT1907"]}],"id":[{"id":"10.13039\/501100006603","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022218","name":"FWF","doi-asserted-by":"publisher","award":["P26011"],"award-info":[{"award-number":["P26011"]}],"id":[{"id":"10.13039\/501100022218","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022218","name":"FWF","doi-asserted-by":"publisher","award":["P29251"],"award-info":[{"award-number":["P29251"]}],"id":[{"id":"10.13039\/501100022218","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022218","name":"FWF","doi-asserted-by":"publisher","award":["P34781"],"award-info":[{"award-number":["P34781"]}],"id":[{"id":"10.13039\/501100022218","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001821","name":"Vienna Science and Technology Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001821","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001821","name":"WWTF","doi-asserted-by":"publisher","award":["N. LS19-018"],"award-info":[{"award-number":["N. LS19-018"]}],"id":[{"id":"10.13039\/501100001821","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Prognosis and quality of life in patients with advanced cutaneous T-cell lymphoma (CTCL), particularly in those with S\u00e9zary syndrome (SS) or advanced-stage mycosis fungoides (MF), are poor. Monoclonal antibodies or antibody\u2013drug conjugates (ADCs) have been added into CTCL treatment algorithms, but the spectrum of antibody-targetable cell surface antigens in T-cell non-Hodgkin lymphomas (T-NHLs) is limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the expression of the major histocompatibility complex class II chaperone CD74 in common subtypes of CTCL by various methods, and to explore the efficacy of targeting CD74 in CTCL cells with an anti-CD74 ADC in vitro and in vivo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We comprehensively investigated the expression of CD74 in well-defined CTCL cell lines by polymerase chain reaction, immunoblotting and flow cytometry. More than 140 primary CTCL samples of all common subtypes were analysed by immunohistochemistry, flow cytometry, immunofluorescence and \u2018co-detection by indexing\u2019 (CODEX) multiplexed tissue imaging, as well as by single-cell RNA sequencing (scRNAseq) analyses. DNA methylation of CTCL cell lines was interrogated by the generation of genome-wide methylation profiling. The effect of a maytansinoid-conjugated humanized ADC against CD74 was investigated in CTCL cell lines in vitro, alone or in combination with gemcitabine, and in vivo after xenotransplantation of CTCL cell lines in NOD-scid Il2rgnull mice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We demonstrated that CD74 is widely and robustly expressed in CTCL cells. In addition, CD74 expression in SS and MF was confirmed by scRNAseq data analysis and was correlated in CTCL cell lines with CD74 DNA hypomethylation. CD74 was rapidly internalized in CTCL cells and CD74 targeting by the ADC STRO-001 efficiently killed CTCL-derived cell lines. Finally, targeting of CD74 synergized with conventional chemotherapy in vitro and eradicated murine xenotransplants of CTCL cell lines in vivo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>CD74 is expressed in common CTCL subtypes. Targeting CD74 efficiently killed CTCL cells in vitro and in vivo. We therefore suggest the targeting of CD74 to be a highly promising treatment strategy for CTCL.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljaf001","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T21:24:03Z","timestamp":1741123443000},"page":"883-895","source":"Crossref","is-referenced-by-count":9,"title":["Preclinical <i>in vitro<\/i> and <i>in vivo<\/i> evidence for targeting CD74 as an effective treatment strategy for cutaneous T-cell lymphomas"],"prefix":"10.1093","volume":"192","author":[{"given":"Mariantonia","family":"Costanza","sequence":"first","affiliation":[{"name":"Max-Delbr\u00fcck-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas , Berlin ,","place":["Germany"]},{"name":"Hematology, Oncology and Cancer Immunology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate member of Freie Universit\u00e4t and Humboldt-Universit\u00e4t zu Berlin , Berlin ,","place":["Germany"]},{"name":"Experimental and Clinical Research Center (ECRC) , a joint cooperation between Charit\u00e9 and MDC, Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catello","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Christin","family":"von Br\u00fcnneck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Makky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Vinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivonne Aidee","family":"Montes-Mojarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Reisinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Forchhammer","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) , Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Witalisz-Siepracka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Edtmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Stoiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Horst","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) , Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiner","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan\u00a0P","family":"Nicolay","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) , Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghong","family":"Yin","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) , Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Janz","sequence":"additional","affiliation":[{"name":"Max-Delbr\u00fcck-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas , Berlin ,","place":["Germany"]},{"name":"Hematology, Oncology and Cancer Immunology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate member of Freie Universit\u00e4t and Humboldt-Universit\u00e4t zu Berlin , Berlin ,","place":["Germany"]},{"name":"Experimental and Clinical Research Center (ECRC) , a joint cooperation between Charit\u00e9 and MDC, Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5496-293X","authenticated-orcid":false,"given":"Falko","family":"Fend","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) , Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen C","family":"Becker","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) , Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian M","family":"Sch\u00fcrch","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) , Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2184-1338","authenticated-orcid":false,"given":"Lukas","family":"Kenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chalid","family":"Assaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Merkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Mathas","sequence":"additional","affiliation":[{"name":"Max-Delbr\u00fcck-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas , Berlin ,","place":["Germany"]},{"name":"Hematology, Oncology and Cancer Immunology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate member of Freie Universit\u00e4t and Humboldt-Universit\u00e4t zu Berlin , Berlin ,","place":["Germany"]},{"name":"Experimental and Clinical Research Center (ECRC) , a joint cooperation between Charit\u00e9 and MDC, Berlin ,","place":["Germany"]},{"name":"German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) , Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"2025042813571641500_ljaf001-B1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"2025042813571641500_ljaf001-B2","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"2025042813571641500_ljaf001-B3","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol"},{"key":"2025042813571641500_ljaf001-B4","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1158\/1078-0432.CCR-12-0604","article-title":"Long-term outcomes of 1,263 patients with mycosis fungoides and S\u00e9zary syndrome from 1982 to 2009","volume":"18","author":"Talpur","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2025042813571641500_ljaf001-B5","first-page":"71","article-title":"Lack of durable disease control with chemotherapy for mycosis fungoides and S\u00e9zary syndrome: a comparative study of systemic therapy","volume-title":"Blood","author":"Hughes","year":"2015"},{"key":"2025042813571641500_ljaf001-B6","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1111\/jdv.17570","article-title":"Quality of life in patients with mycosis fungoides and S\u00e9zary syndrome: a systematic review of the literature","volume":"35","author":"Ottevanger","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025042813571641500_ljaf001-B7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ajh.26760","article-title":"Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Hristov","year":"2023","journal-title":"Am J Hematol"},{"key":"2025042813571641500_ljaf001-B8","doi-asserted-by":"crossref","first-page":"113343","DOI":"10.1016\/j.ejca.2023.113343","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary \u00adsyndrome\u00a0\u2013 update 2023","volume":"195","author":"Latzka","year":"2023","journal-title":"Eur J Cancer"},{"key":"2025042813571641500_ljaf001-B9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41568-020-0247-0","article-title":"Peripheral T cell lymphomas: from the bench to the clinic","volume":"20","author":"Fiore","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"2025042813571641500_ljaf001-B10","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.3390\/cancers13195012","article-title":"Aberrant expression of and cell death induction by engagement of the MHC-II chaperone CD74 in anaplastic large cell lymphoma (ALCL)","volume":"13","author":"Wurster","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025042813571641500_ljaf001-B11","doi-asserted-by":"crossref","first-page":"5831","DOI":"10.1073\/pnas.0900912106","article-title":"Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma","volume":"106","author":"Mathas","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025042813571641500_ljaf001-B12","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.bbamcr.2016.03.026","article-title":"The multifaceted roles of the invariant chain CD74\u00a0\u2013 more than just a chaperone","volume":"1863","author":"Schr\u00f6der","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"2025042813571641500_ljaf001-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-4889(01)00166-5","article-title":"Multiple roles of the invariant chain in MHC class II function","volume":"1542","author":"Stumptner-Cuvelette","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"2025042813571641500_ljaf001-B14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00011-016-0995-1","article-title":"The biological function and significance of CD74 in immune diseases","volume":"66","author":"Su","year":"2017","journal-title":"Inflamm Res"},{"key":"2025042813571641500_ljaf001-B15","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-47981-3","article-title":"CD74 supports accumulation and function of regulatory T cells in tumors","volume":"15","author":"Bonnin","year":"2024","journal-title":"Nat Commun"},{"key":"2025042813571641500_ljaf001-B16","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1182\/blood-2019-122754","article-title":"Preliminary results of a phase 1 dose escalation study of the first-in-class anti-CD74 antibody drug conjugate (ADC), STRO-001, in patients with advanced B-cell malignancies","volume":"134","author":"Shah","year":"2019","journal-title":"Blood"},{"key":"2025042813571641500_ljaf001-B17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/bjh.14726","article-title":"A phase I\u2013II clinical trial of the anti-CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia: a patient based approach","volume":"182","author":"Haran","year":"2018","journal-title":"Br J Haematol"},{"key":"2025042813571641500_ljaf001-B18","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/bjh.12565","article-title":"Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma","volume":"163","author":"Kaufman","year":"2013","journal-title":"Br J Haematol"},{"key":"2025042813571641500_ljaf001-B19","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.3109\/10428194.2015.1028052","article-title":"Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas","volume":"56","author":"Martin","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2025042813571641500_ljaf001-B20","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.13354","article-title":"The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma","volume":"169","author":"Christian","year":"2015","journal-title":"Br J Haematol"},{"key":"2025042813571641500_ljaf001-B21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s40164-023-00437-8","article-title":"A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models","volume":"12","author":"Chan","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"2025042813571641500_ljaf001-B22","doi-asserted-by":"crossref","first-page":"37700","DOI":"10.18632\/oncotarget.26491","article-title":"Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001","volume":"9","author":"Abrahams","year":"2018","journal-title":"Oncotarget"},{"key":"2025042813571641500_ljaf001-B23","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-25379-9","article-title":"Super-enhancer-based identification of a BATF3\/IL-2R-module reveals vulnerabilities in anaplastic large cell lymphoma","volume":"12","author":"Liang","year":"2021","journal-title":"Nat Commun"},{"key":"2025042813571641500_ljaf001-B24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1365-2133.2012.10918.x","article-title":"The tumour suppressor p53 is frequently nonfunctional in S\u00e9zary syndrome","volume":"167","author":"Lamprecht","year":"2012","journal-title":"Br J Dermatol"},{"key":"2025042813571641500_ljaf001-B25","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1093\/emboj\/cdf389","article-title":"Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B","volume":"21","author":"Mathas","year":"2002","journal-title":"EMBO J"},{"key":"2025042813571641500_ljaf001-B26","doi-asserted-by":"crossref","first-page":"1408614","DOI":"10.3389\/fonc.2024.1408614","article-title":"Single-cell RNA and T-cell receptor sequencing unveil mycosis fungoides heterogeneity and a possible gene signature","volume":"14","author":"Srinivas","year":"2024","journal-title":"Front Oncol"},{"key":"2025042813571641500_ljaf001-B27","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/bloodadvances.2021005991","article-title":"Single-cell analysis of S\u00e9zary syndrome reveals novel markers and shifting gene profiles associated with treatment","volume":"7","author":"Borcherding","year":"2023","journal-title":"Blood Adv"},{"key":"2025042813571641500_ljaf001-B28","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3390\/cells11040593","article-title":"Understanding cell lines, patient-derived xenograft and genetically engineered mouse models used to study cutaneous T-cell lymphoma","volume":"11","author":"Gill","year":"2022","journal-title":"Cells"},{"key":"2025042813571641500_ljaf001-B29","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1056\/NEJM199204233261704","article-title":"Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone","volume":"326","author":"Davis","year":"1992","journal-title":"N Engl J Med"},{"key":"2025042813571641500_ljaf001-B30","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1084\/jem.20030286","article-title":"MIF signal transduction initiated by binding to CD74","volume":"197","author":"Leng","year":"2003","journal-title":"J Exp Med"},{"key":"2025042813571641500_ljaf001-B31","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.immuni.2006.08.020","article-title":"CD44 is the signaling component of the macrophage migration inhibitory factor\u2013CD74 receptor complex","volume":"25","author":"Shi","year":"2006","journal-title":"Immunity"},{"key":"2025042813571641500_ljaf001-B32","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1016\/j.febslet.2009.07.058","article-title":"A functional heteromeric MIF receptor formed by CD74 and CXCR4","volume":"583","author":"Schwartz","year":"2009","journal-title":"FEBS Lett"},{"key":"2025042813571641500_ljaf001-B33","author":"Mathur"},{"key":"2025042813571641500_ljaf001-B34","first-page":"177","article-title":"Surface expression of the invariant chain (CD74) is independent of concomitant expression of major histocompatibility complex class II antigens","volume":"84","author":"Henne","year":"1995","journal-title":"Immunology"},{"key":"2025042813571641500_ljaf001-B35","doi-asserted-by":"crossref","first-page":"18545","DOI":"10.1016\/S0021-9258(19)81393-5","article-title":"Brefeldin A causes disassembly of the Golgi complex and accumulation of secretory proteins in the endoplasmic reticulum","volume":"263","author":"Fujiwara","year":"1988","journal-title":"J Biol Chem"},{"key":"2025042813571641500_ljaf001-B36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0092-8674(00)80724-2","article-title":"Brefeldin A: the advantage of being uncompetitive","volume":"97","author":"Chardin","year":"1999","journal-title":"Cell"},{"key":"2025042813571641500_ljaf001-B37","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1126\/science.146.3650.1474","article-title":"Cycloheximide: aspects of inhibition of protein synthesis in mammalian cells","volume":"146","author":"Ennis","year":"1964","journal-title":"Science"},{"key":"2025042813571641500_ljaf001-B38","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.4049\/jimmunol.132.4.1900","article-title":"A human Ia cytoplasmic determinant located on multiple forms of invariant chain (gamma, gamma 2, gamma 3)","volume":"132","author":"Quaranta","year":"1984","journal-title":"J Immunol"},{"key":"2025042813571641500_ljaf001-B39","first-page":"106","volume-title":"Fourth International Workshop and Conference on Human Leucocyte Differentiation Antigens, Vienna, 21\u201325 February 1989","author":"D\u00f6rken","year":"1989"},{"key":"2025042813571641500_ljaf001-B40","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1189\/jlb.0805461","article-title":"Modulation of specific surface receptors and activation sensitization in primary resting CD4+ T lymphocytes by the Nef protein of HIV-1","volume":"79","author":"Keppler","year":"2006","journal-title":"J Leukoc Biol"},{"key":"2025042813571641500_ljaf001-B41","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1158\/1078-0432.CCR-10-0671","article-title":"Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies","volume":"16","author":"Marchi","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2025042813571641500_ljaf001-B42","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ng.3444","article-title":"Genomic profiling of S\u00e9zary syndrome identifies alterations of key T cell signaling and differentiation genes","volume":"47","author":"Wang","year":"2015","journal-title":"Nat Genet"},{"key":"2025042813571641500_ljaf001-B43","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00262-008-0632-0","article-title":"Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD\/Shi-scid, IL-2Rgamma(null) mouse model","volume":"58","author":"Ito","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"2025042813571641500_ljaf001-B44","doi-asserted-by":"crossref","first-page":"6494","DOI":"10.1158\/1078-0432.CCR-07-1324","article-title":"Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive\/refractory mycosis fungoides and S\u00e9zary syndrome","volume":"13","author":"Yano","year":"2007","journal-title":"Clin Cancer Research"},{"key":"2025042813571641500_ljaf001-B45","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1182\/bloodadvances.2020002395","article-title":"ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells","volume":"4","author":"Amatore","year":"2020","journal-title":"Blood Adv"},{"key":"2025042813571641500_ljaf001-B46","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/2211-5463.13625","article-title":"CCR4\u2013IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model","volume":"13","author":"Wang","year":"2023","journal-title":"FEBS Open Bio"},{"key":"2025042813571641500_ljaf001-B47","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-14-2249","article-title":"Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma","volume":"21","author":"Jain","year":"2015","journal-title":"Clin Cancer Research"},{"key":"2025042813571641500_ljaf001-B48","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/annrheumdis-2020-219803","article-title":"Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE)","volume":"80","author":"Wallace","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025042813571641500_ljaf001-B49","doi-asserted-by":"crossref","first-page":"e170015","DOI":"10.1172\/jci.insight.170015","article-title":"The mycosis fungoides cutaneous microenvironment shapes dysfunctional cell trafficking, antitumor immunity, matrix interactions, and angiogenesis","volume":"8","author":"Gaydosik","year":"2023","journal-title":"JCI Insight"},{"key":"2025042813571641500_ljaf001-B50","first-page":"2780","article-title":"The microenvironment's role in mycosis fungoides and S\u00e9zary syndrome: from progression to therapeutic implications","volume-title":"Cells","author":"Pileri","year":"2021"},{"key":"2025042813571641500_ljaf001-B51","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/exd.12894","article-title":"Mac attack: macrophages as key drivers of cutaneous T-cell lymphoma pathogenesis","volume":"25","author":"Assaf","year":"2016","journal-title":"Exp Dermatol"},{"key":"2025042813571641500_ljaf001-B52","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood.V89.1.32.32_32_40","article-title":"Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion","volume":"89","author":"Jackow","year":"1997","journal-title":"Blood"},{"key":"2025042813571641500_ljaf001-B53","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1182\/blood.2023021671","article-title":"Staphylococcus aureus induces drug resistance in cancer T cells in S\u00e9zary syndrome","volume":"143","author":"Vadivel","year":"2024","journal-title":"Blood"},{"key":"2025042813571641500_ljaf001-B54","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1182\/blood.2018888107","article-title":"Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma","volume":"134","author":"Lindahl","year":"2019","journal-title":"Blood"},{"key":"2025042813571641500_ljaf001-B55","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.4049\/jimmunol.156.6.2133","article-title":"Phenotype and function of CD4+ T cells in mice lacking invariant chain","volume":"156","author":"Wong","year":"1996","journal-title":"J Immunol"},{"key":"2025042813571641500_ljaf001-B56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18632\/oncotarget.28341","article-title":"Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001","volume":"14","author":"Li","year":"2023","journal-title":"Oncotarget"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf001\/62198397\/ljaf001.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/5\/883\/62198397\/ljaf001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/5\/883\/62198397\/ljaf001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T17:57:33Z","timestamp":1745863053000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/192\/5\/883\/8045421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":56,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,2,27]]},"published-print":{"date-parts":[[2025,4,28]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf001","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,2,27]]}}}